14 Participants Needed

Casdatifan Interaction Study in Healthy Subjects

AB
Overseen ByArcus Biosciences
Age: 18 - 65
Sex: Any
Trial Phase: Phase 1
Sponsor: Arcus Biosciences, Inc.
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

What is the purpose of this trial?

The purpose of the study is to assess the effects of multiple doses of itraconazole (a strong CYP3A4 inhibitor) on single dose PK of casdatifan in healthy adults and to assess the effects of multiple doses of phenytoin (a strong CYP3A4 inducer) on single dose PK of casdatifan in healthy adults.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. However, since the study involves assessing drug interactions, it's possible that changes to your medication regimen might be required. Please consult with the study team for specific guidance.

What makes the drug Casdatifan unique compared to other treatments?

Casdatifan is unique because it focuses on drug interactions, particularly with food and other substances, which can vary greatly among individuals. This approach is different from many treatments that do not specifically address these interactions, making it potentially safer for people who are more susceptible to side effects from such interactions.12345

Research Team

MD

Medical Director

Principal Investigator

Arcus Biosciences

Eligibility Criteria

This trial is for healthy adults who can participate in a study to understand how casdatifan, a drug under investigation, interacts with other medications. Specific eligibility criteria are not provided.

Inclusion Criteria

I am a male and have had a vasectomy.
I haven't smoked or used nicotine products for over 3 months.
My BMI is between 18 and 32, and I weigh at least 45 kg.
See 1 more

Exclusion Criteria

History of any illness that, in the opinion of the PI or designee, might confound the results of the study or poses an additional risk to the participant by their participation in the study
History or presence of hypersensitivity or idiosyncratic reaction to the study drugs or related compounds
I have a significant health or mental condition.
See 2 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive casdatifan with itraconazole and phenytoin to assess drug-drug interactions

4 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Treatment Details

Interventions

  • Casdatifan
Trial Overview The study is testing the interactions between casdatifan and two other drugs: itraconazole, which inhibits certain enzymes, and phenytoin, which induces them. The goal is to see how these drugs affect the presence of casdatifan in the body when taken together.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: Casdatifan-Itraconazole-PhenytoinExperimental Treatment3 Interventions
Participants will receive casdatifan, itraconazole, and phenytoin.

Find a Clinic Near You

Who Is Running the Clinical Trial?

Arcus Biosciences, Inc.

Lead Sponsor

Trials
44
Recruited
7,500+

References

[Drug/food interactions: an actual therapeutic outcome]. [2013]
Relative prevalence of 10 types of pharmacodynamic interactions in psychiatric treatment. [2020]
Gender differences, polypharmacy, and potential pharmacological interactions in the elderly. [2022]
Pharmacokinetic and Pharmacodynamic Drug-Drug Interactions: Research Methods and Applications. [2023]
In vitro CYP450 enzyme down-regulation by GLP-1/glucagon co-agonist does not translate to observed drug-drug interactions in the clinic. [2022]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security